Metaplastic breast carcinoma: Analysis of 31 cases from a single institute

Autor: Henney G. Amanguno, Sadeq Abuzalouf, Salah Fayaz, Heba El-Sayed Eissa, Gerges Attia Demian
Rok vydání: 2017
Předmět:
Adult
0301 basic medicine
Oncology
medicine.medical_specialty
Metaplastic carcinoma
medicine.medical_treatment
Population
Breast Neoplasms
lcsh:RC254-282
03 medical and health sciences
Metaplastic
0302 clinical medicine
Breast cancer
Internal medicine
Carcinosarcoma
Biomarkers
Tumor
Materials Chemistry
medicine
Humans
Breast
Neoplasm Metastasis
skin and connective tissue diseases
education
Aged
Neoplasm Staging
Cancer
Outcome
Metaplasia
education.field_of_study
business.industry
Middle Aged
Metaplastic Breast Carcinoma
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Combined Modality Therapy
Survival Analysis
Treatment Outcome
030104 developmental biology
Clinicopathological
030220 oncology & carcinogenesis
Female
Neoplasm Grading
Breast carcinoma
business
Mastectomy
Zdroj: Journal of the Egyptian National Cancer Institute, Vol 29, Iss 3, Pp 141-145 (2017)
ISSN: 1110-0362
DOI: 10.1016/j.jnci.2017.05.002
Popis: Purpose Metaplastic carcinoma of the breast (MBC) accounts for less than 1% of all mammary tumors. This study aimed at revision of the clinico-pathological features, treatment strategy and outcome for MBC patients presented to the Kuwait Cancer Control Center to define the clinical behavior and prognostic factors of these neoplasms in our population. Patient and methods Thirty-one patients were retrieved from our surgical pathology registry between January 2005 and December 2014. Medical records were revised regarding the clinico-pathological features and treatment outcome. Results MBC represented 1% of our breast cancer patients. The median age was 50 years (32–70 years). Two patients presented with metastatic disease. Mastectomy was done for 24 patients and 7 had conservative surgery. The median tumor size at the time of surgery was 5.5 cm (1.5–12 cm). Axillary nodes were negative in 21 patients (N0), 5 patients were N1, 4 patients were N2 and one Nx. Three histological subtypes were presented: carcinosarcoma (7 cases), squamous cell carcinoma/IDC with squamous differentiation (15 cases), high grade IDC with metaplastic differentiation (9 cases). Immunohistochemically, 26 were negative hormone receptors and all were negative for Her2/neu overexpression. Chemotherapy was used in 28 patients, and adjuvant radiotherapy in 24 patients. The median follow-up was 47 months (7–126 months), six patients lost follow-up. The 5-year OS was 69% and 5-year PFS was 50%. Conclusion MBC is a rare entity among breast carcinoma in Kuwait. Most of the cases present with poor prognostic indicators and often show lack of expression of ER, PR and Her2/neu.
Databáze: OpenAIRE
Externí odkaz: